Phase 2 Lung Cancer Trial, Recruiting (NCT06749691)

Phase 2 Lung Cancer Trial, Recruiting NCT06749691 Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06749691 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People between 18 and 75 years of age
People whose doctors expect them to live for at least 12 weeks
People who have at least one tumour or lesion that can be measured on a scan, based on standard measurement guidelines
People whose cancer has continued to grow or has returned after one or two previous treatment attempts

Who may not be able to join:

People who have previously received any treatment that targets blood vessel growth (known as anti-angiogenic therapy), such as ranibizumab, fipaxinib, apatinib, anlotinib, lenvatinib, sunitinib, or sorafenib
People who have a severe active infection that is not under control, or who have been treated with antibiotics within the 2 weeks before joining the trial
People who have difficulty absorbing oral (swallowed) medication due to conditions such as an inability to swallow, ongoing nausea and vomiting, chronic diarrhoea, or a bowel blockage
People whom the treating doctor considers unsuitable for participation in the trial for any reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 20 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 86-571-86993769

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06749691

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase: Phase 2

Status: Recruiting

Condition: Lung Cancer

Trial contact: 86-571-86993769

More information: https://clinicaltrials.gov/study/NCT06749691

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People between 18 and 75 years of age
People whose doctors expect them to live for at least 12 weeks
People who have at least one tumour or lesion that can be measured on a scan, based on standard measurement guidelines
People whose cancer has continued to grow or has returned after one or two previous treatment attempts

Who may not be able to join:

People who have previously received any treatment that targets blood vessel growth (known as anti-angiogenic therapy), such as ranibizumab, fipaxinib, apatinib, anlotinib, lenvatinib, sunitinib, or sorafenib
People who have a severe active infection that is not under control, or who have been treated with antibiotics within the 2 weeks before joining the trial
People who have difficulty absorbing oral (swallowed) medication due to conditions such as an inability to swallow, ongoing nausea and vomiting, chronic diarrhoea, or a bowel blockage
People whom the treating doctor considers unsuitable for participation in the trial for any reason

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 20 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Registry

ClinicalTrials.gov

Start date

28 December 2024

Est. completion

1 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progression-Free-Survival rate at 6 months

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov